Prosperity Consulting Group LLC Has $1.97 Million Stock Position in Sanofi (NASDAQ:SNY)

Prosperity Consulting Group LLC cut its stake in shares of Sanofi (NASDAQ:SNY) by 6.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 35,533 shares of the company’s stock after selling 2,364 shares during the period. Prosperity Consulting Group LLC’s holdings in Sanofi were worth $1,971,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the company. Invesco Ltd. increased its position in Sanofi by 3.5% during the fourth quarter. Invesco Ltd. now owns 12,059,283 shares of the company’s stock worth $581,619,000 after acquiring an additional 408,752 shares during the period. Bank of America Corp DE increased its holdings in shares of Sanofi by 3.8% during the fourth quarter. Bank of America Corp DE now owns 12,017,140 shares of the company’s stock worth $579,587,000 after purchasing an additional 441,637 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Sanofi by 88.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company’s stock valued at $522,991,000 after buying an additional 5,091,304 shares during the period. Franklin Resources Inc. grew its position in Sanofi by 10.8% during the fourth quarter. Franklin Resources Inc. now owns 3,776,982 shares of the company’s stock worth $182,164,000 after buying an additional 369,530 shares in the last quarter. Finally, Nuveen Asset Management LLC increased its stake in Sanofi by 1.0% during the 4th quarter. Nuveen Asset Management LLC now owns 3,676,224 shares of the company’s stock worth $177,304,000 after acquiring an additional 34,660 shares during the period. Institutional investors own 14.04% of the company’s stock.

Sanofi Stock Down 1.8%

Sanofi stock opened at $49.48 on Tuesday. The firm has a 50 day moving average price of $49.49 and a two-hundred day moving average price of $52.15. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37. Sanofi has a 52-week low of $45.80 and a 52-week high of $60.12. The firm has a market cap of $121.35 billion, a price-to-earnings ratio of 17.67, a PEG ratio of 1.15 and a beta of 0.48.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Hsbc Global Res upgraded Sanofi to a “strong-buy” rating in a research report on Monday, April 28th. BNP Paribas assumed coverage on Sanofi in a research report on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 target price on the stock. Barclays reaffirmed an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. Morgan Stanley set a $56.00 price target on Sanofi in a research note on Monday, June 2nd. Finally, Guggenheim restated a “buy” rating on shares of Sanofi in a research report on Tuesday, June 3rd. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $62.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.